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Objective. The purpose of this study was to examine the utility of the one-step nucleic acid ampliﬁcation
(OSNA) assay using cytokeratin (CK) 19 (KRT19) messenger RNA (mRNA) for the detection of sentinel lymph
node (SLN) metastases in cervical cancer patients.
Methods. To determine a cutoff value, KRT19 mRNA was assessed by OSNA assay using 239 lymph nodes
(LNs) (217 histopathologically negative LNs and 22 positive LNs). A cutoff value was determined by statistical
analysis of the copy numbers obtained by OSNA assay. Subsequently, performance evaluation of the OSNA
assay (applying the cutoff value above) on 130 SLNs (32 patients) was used to investigate (through concor-
dance) whether the OSNA assay exhibited diagnostic performance equivalent to the two-mm interval histo-
pathological examination.
Results. Two hundred ﬁfty copies/μL of KRT19 mRNA in the OSNA assay appeared to be an optimal cutoff
value. In performance evaluation of the OSNA assay, we identiﬁed ﬁve positive SLNs and 125 negative SLNs
by OSNA assay using KRT19 mRNA, exhibiting 96.2% agreement with two-mm interval histopathological
examination.
Conclusions. Our results indicated that the KRT19 mRNA OSNA assay can detect LN metastases as ac-
curately as two-mm interval histopathological examination and thus may be an effective additional or
alternative method for a rapid intra-operative examination of SLNs in cervical cancer.© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
The sentinel lymph node (SLN) is thought to be the ﬁrst point
of microscopic metastatic spread. According to the SLN hypothesis,ra).
nc. Open access under CC BY-NC-ND licenselymph node (LN) dissection can be omitted when no metastases are
detected in the SLNs. The utility of SLN mapping in melanoma and
breast cancer is widely accepted. Evaluation of the SLN in these
cancers increases the detection rate of micrometastases while mini-
mizing operative morbidity [1,2]. The role of SLN mapping in gyneco-
logic malignancies has not been established [3–7].
Bats et al. investigated the diagnostic value of intra-operative ex-
amination with frozen sections (FS) or imprint cytology (IC) of SLNs
in early cervical cancer [8]. When SLNs were cut in half along their
long axis, they reported that FS and IC had poor diagnostic values
(sensitivity was 22.7%). In our previous study and that of Gortzak-Uzan.
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parallel to the node [9,10]. None of the patients who were diagnosed
intra-operatively with negative SLNs experienced a LN recurrence
in the pelvic cavity [9]. The prognosis did not change as compared to
systemic pelvic lymphadenectomy [10]. Consequently, step sectioning
at two-mm intervals parallel to the node could be effective for intra-
operative examination of SLN. However, it might overlook micro-
metastases and force a heavy workload on technicians and pathologists.
Reports investigating the prognostic signiﬁcance of micrometastases
are limited. When classiﬁed according to the American Joint Committee
on Cancer Criteria for breast cancer, micrometastases in cervical cancers
are signiﬁcantly associated with decreased overall survival and de-
creased time to recurrence [11,12]. In general, analysis of SLN biopsies
using serial sectioning (0.04–0.25-mm intervals) combinedwith immu-
nohistochemistry (IHC) appears to be more reliable at detecting
micrometastases than routine hematoxylin and eosin (H&E) histology
[13,14]. However, these methods have not been applied to intra-
operative examination because they are too cumbersome, time-
consuming, and costly to be used in routine examination [15,16]. There-
fore, a quick, reliable, and reproducible method for LN analysis is
necessary.
The one-step nucleic acid ampliﬁcation (OSNA) assay is already in
use for clinical diagnosis of LN metastases in breast cancer [17–21].
However, the ability of OSNA to detect LN metastases in cervical can-
cer has not been investigated. Therefore, the purpose of this study
was to determine whether the assessment of cytokeratin (CK) 19
(KRT19) mRNA with the OSNA assay could be successfully used for
the detection of LN metastases in cervical cancer.
Material and methods
LN acquisition for selecting mRNA markers and determining cutoff values
LNs of cervical cancer patients were obtained at Tohoku University
Hospital and Cancer Institute Hospital and were stored at −80 °C
until use. LNs were obtained with the approval of the institutional in-
ternal review boards at both facilities.
qRT-PCR for selecting mRNA
mRNA was extracted from the LNs according to the following pro-
cedure. Four milliliters of lysis buffer (Lynorhag; Sysmex, Kobe,
Japan) was added to the LN. The tissue was homogenized for 90 s
on ice using a Physicotron Waring blender with an NS-7 shaft
(MicroTec Nichion, Tokyo, Japan). The homogenate was centrifuged
at 10,000 ×g for 60 s at room temperature. RNA was puriﬁed from
the LN lysate using the RNeasy Mini Kit (Qiagen, Hamburg, Germany),
and puriﬁed RNA was then subjected to qRT-PCR with QuantiTect
SYBER Green (Qiagen) according to the manufacturer's instructions.
The primers were designed in Primer Express Version 2.0 software
(Applied Biosystems, Foster City, CA), and qRT-PCR was performed
with a 7500 Real-Time PCR System (Applied Biosystems). The expres-
sion level of each mRNA was evaluated on Ct value.
Selection of optimal mRNA markers
Identiﬁcation of candidate mRNA markers
We set out to conﬁrm that KRT19 mRNA was an optimal marker.
CandidatemRNAmarkerswere identiﬁed in theNational Center for Bio-
technology Information Gene Expression Omnibus (GEO; http://www.
ncbi.nlm.nih.gov/geo/) database. Affymetrix U133 or U133 + 2.0 was
used to examine mRNA expression in cervical cancer and normal LNs.
Sixty-ﬁve gene expression data sets of primary tumors from GSE9750
and GSE5787, and ten LN (GSE2665) mRNA expression data sets
were selected from the GEO database. The data were normalized to
β-actin after z-score transformation. Candidate markers were selectedas genes with high expression in cervical cancer and low expression in
normal LNs, exhibiting differences in expression of more than 100-fold.
First selection to identify optimal mRNA markers
The performance of these mRNA markers was evaluated with
qRT-PCR using a mixture of each histological type of eight histopath-
ologically positive and eight histologically negative LNs. Positive LNs
were obtained from four squamous cell carcinomas (SCCs) and four
adenocarcinomas (ACs) from eight patients. Negative LNs were
obtained from four SCCs and four ACs from eight patients. For the
preparation of LNs for qRT-PCR, the LN was ﬁrst divided in half into
blocks a and b. The central part of block a was then dissected (termed
block c). The remainder of block a, called block a-prime, was used for
qRT-PCR. Block c was used for histopathological examination with
H&E and IHC of CK (AE1/AE3, DAKO) staining (Fig. 1A).
Second selection of optimal mRNA markers
The selected markers were further evaluated with qRT-PCR using
individual LNs of 16 histopathologically positive and 16 histopatho-
logically negative LNs from 32 patients. The optimal marker for
diagnosis was then determined. Positive LNs were obtained from 16
patients (eight SCCs and eight ACs). Negative LNs were obtained
from eight SCCs and eight ACs from 16 patients. Preparation of LNs
was conducted using the method described above (Fig. 1A).
Establishment of cutoff values
A cutoff value for the OSNA assay using the KRT19 mRNA marker
was determined using 239 LNs (both positive and negative) from 59
patients. The OSNA assay was performed, as previously described
[17]. Positive LNs included 11 SCCs from six patients and 11 ACs
from six patients. Additionally, 163 negative LNs were obtained
from pN0 patients, and 54 negative LNs were obtained from pN1 pa-
tients. A cutoff value was determined by receiver operating character-
istic curve (ROC) analysis of the copy numbers obtained by the OSNA
assay. Preparation of LNs was conducted using the method described
above (Fig. 1A).
Performance evaluation
Performance evaluation of the OSNA assay with KRT19mRNA was
used to investigate (through concordance) whether the OSNA assay
exhibited diagnostic performance equivalent to the two-mm interval
histopathological examination, as previously described [17]. One
hundred thirty SLNs from 32 patients were obtained from Tohoku
University Hospital between April, 2009 and January, 2013 with the
approval of the institutional internal review board. The clinicopatho-
logical characteristics of these patients are summarized in Table 1.
Seventeen consecutive patients (cases one to 17) included those
with SLN biopsy alone group without SLN metastasis and with sys-
tematic pelvic lymphadenectomy group with SLN metastasis. In our
study protocol for radical hysterectomy with SLN biopsy alone [9], pa-
tients with International Federation of Gynecology and Obstetrics
stage IA1 (with severe lymphovascular space involvement), IA2, IB1,
or IIA1 disease were eligible for study participation. Exclusion criteria
included evidence of LN metastases and/or tumors more than 3 cm
onmagnetic resonance imaging and/or computed tomography at pre-
operative evaluation. Patients in whom SLNs were detected unilater-
ally or not detected and/or who had a diagnosis of positive LN
metastasis intra-operatively underwent systematic pelvic lymphade-
nectomy. Patients who were found negative for SLN metastasis did
not undergo further pelvic lymphadenectomy. Cases 18 to 20 includ-
ed the AC patients with systematic pelvic lymphadenectomy. Cases
21 to 32 included those who received a radical trachelectomy with
systematic pelvic lymphadenectomy.
Fig. 1. (A) Protocol for determining optimal markers and cutoff values. Block a-prime was used for qRT-RCR or OSNA assays. Block c was used for histopathological examination.
(B) Protocol for evaluating performance. SLNs were serially sectioned at two mm intervals perpendicular to the short axis. All cut surfaces were subjected to histopathological ex-
amination with H&E. Even numbered blocks were analyzed by OSNA. OSNA, one-step nucleic acid ampliﬁcation.
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operatively. Each SLN was examined using step sectioning at two-
mm intervals parallel to the short axis of the node and examined
with H&E. For example, the ﬁve-μm thick sections that had been pre-
pared from all three cut surfaces were subjected to histopathological
examination with H&E after the SLN was divided into four sections
(Fig. 1B). After histopathological examination, even numbered blocksTable 1
Clinicopathological characteristics of patients for performance evaluation.
Patient Age Clinical stage Histological type
1 37 Ib1 SCC
2 24 Ib1 SCC
3 41 IIb SCC
4 33 Ib1 SCC
5 42 Ib1 SCC
6 45 Ib1 SCC
7 48 Ib1 SCC
8 43 Ib1 SCC
9 35 Ib1 SCC
10 34 Ib1 SCC
11 34 Ib1 SCC
12 31 Ia2 SCC
13 37 Ib1 SCC
14 29 Ib1 SCC
15 54 Ia1 SCC
16 57 Ib1 SCC
17 45 Ib1 SCC
18 31 Ib1 AC
19 35 Ia1 AC
20 56 Ib1 AC
21 35 Ib1 SCC
22 27 Ib1 SCC
23 33 Ib1 SCC
24 33 Ia1 SCC
25 39 Ia2 SCC
26 29 Ib1 SCC
27 32 Ib1 SCC
28 32 Ib1 SCC
29 25 Ib1 SCC
30 37 Ib1 AC
31 34 Ib1 SCC
32 25 Ib1 SCC
SLN, sentinel lymph node; OSNA, one-step nucleic acid ampliﬁcation; R, right; L, left; LN, ly
node biopsy; PLA, pelvic lymphadenectomy.were analyzed by OSNA assay using the cutoff value determined as
described above.
In histopathological examinations, macrometastases were deﬁned
as metastatic foci 2 mm or larger along the long axis. Micrometastases
were deﬁned as metastases measuring between 0.2 and 2 mm. A LN
load measuring less than 0.2 mm was designated as an isolated tumor
cell (ITC).Number of metastatic SLNs/total SLNs LN dissection
Histology OSNA
R L R L
0/2 0/1 0/2 0/1 SLNB
0/1 0/1 0/1 0/1 SLNB
0/1 0/1 0/1 0/1 SLNB
0/2 0/1 0/2 0/1 SLNB
0/5 0/2 0/5 0/2 SLNB
0/4 0/1 0/4 0/1 PLA
2/4 0/2 1/4 0/2 PLA
0/2 0/2 0/2 0/2 SLNB
0/1 0/1 0/1 0/1 SLNB
0/7 0/2 0/7 0/2 SLNB
0/4 0/2 0/4 0/2 SLNB
0/1 0/1 0/1 0/1 SLNB
0/1 1/1 1/1 0/1 PLA
0/1 0 0/1 0 PLA
0/2 0/1 0/2 0/1 SLNB
0/3 0/1 0/3 0/1 SLNB
2/3 0/2 2/3 0/2 PLA
0/2 0/2 0/2 0/2 PLA
0/1 0/3 0/1 0/3 PLA
0/2 0/2 1/2 0/2 PLA
0/1 0/2 0/1 0/2 PLA
0/2 1/1 0/2 0/1 PLA
0/2 0/1 0/2 0/1 PLA
0/1 0/3 0/1 0/3 SLNB
0/2 0/2 0/2 0/2 PLA
0/2 0/1 0/2 0/1 PLA
0/1 0/2 0/1 0/2 PLA
0/1 0/2 0/1 0/2 PLA
0/2 0/1 0/2 0/1 PLA
0/1 0/3 0/1 0/3 PLA
0/5 0/1 0/5 0/1 PLA
0/1 0/1 0/1 0/1 PLA
mph node; SCC, squamous cell carcinoma; AC, adenocarcinoma; SLNB, sentinel lymph
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Selection of optimal mRNA markers
Identiﬁcation of candidate mRNA markers
Thirty-one candidate mRNA markers including KRT19mRNA were
selected based on public GEO databases. Furthermore, we included
human papillomavirus (HPV) 16 E6, a previously reported candidate
mRNA marker [22]. A total of 32 mRNA markers were identiﬁed as
potential candidate markers.
First selection for optimal mRNA markers
Of these 32 mRNAs, the expression levels of KRT19, KRT15, KRT17,
KRT4, serpin peptidase inhibitor, clade B member 5 (SERPINB5),
SERPINB3, peptidase inhibitor 3 (PI3), annexin A8 (ANXA8), and FXYD
domain-containing ion transport regulator 3 (FXYD3) were high in the
metastatic LNs of both SCCs and ACs (Fig. 2A). In contrast, the expres-
sion levels of these mRNAs were low in nonmetastatic LNs. Therefore,
these nine mRNAs including KRT19 were selected as optimal markers
for qRT-PCR.
Second selection of optimal mRNA markers
Of these 9 mRNAs, the expression of KRT19, KRT17, SERPINB5,
ANXA8, and FXYD3 mRNAs differed between histopathologically
positive and negative LNs (Fig. 2B). The expression differences (ΔCt
values) between the lower limits of histopathologically positive LNs
and upper limits of histologically negative LNs were 5.4, 1.0, 2.8, 5.3,Fig. 2. (A) First selection results. Thirty-two mRNAmarkers were evaluated with qRT-RCR us
obtained from SCC and AC. (B) Second selection results. Expression of mRNA markers in his
KRT17, KRT4, SERPINB5, SERPINB3, PI3, ANXA8, and FXYD3] were evaluated by qRT-PCR using
obtained from SCCs (▲ and△) and ACs (● and ○). LN, lymph node; KRT, cytokeratin; SERPIN
A8; FXYD, FXYD domain-containing ion transport regulator; HPV, human papillomavirus; Sand 3.7, respectively. KRT19 and ANXA8mRNAs exhibited the greatest
differences between histopathologically positive and histopathologi-
cally negative LNs among these ﬁve mRNA markers. Therefore, KRT19
mRNAwas one of the optimal markers for the OSNA assay in the detec-
tion of LN metastases in cervical cancer.
Establishment of cutoff values
KRT19 mRNA expression assessed in the OSNA assay was com-
pared to that of histopathological examination with H&E and IHC of
CK (AE1/AE3) staining. The results of the assays are expressed as
the number of KRT19 mRNA copies/μL (Fig. 3A). To establish a cutoff
value for the OSNA assay using histopathologically positive and neg-
ative LNs, we evaluated the sensitivity and speciﬁcity of serial cutoff
values (25–5000 copies/μL) in ROC (Fig. 3B). In this evaluation, cutoff
values of both 100 and 250 copies/μL showed superior sensitivities
and speciﬁcities to the other tested cutoff values. When histological
procedures were taken as the gold standard, the positive predictive
value obtained by setting the cutoff value to 250 copies/μL (90.9%)
was superior to the cutoff value of 100 copies/μL (61.8%). Based on
this analysis, we set the cutoff value for KRT19 mRNA in the OSNA
assay to 250 copies/μL.
Performance evaluation
We divided the 32 patients into a systematic pelvic lymphadenec-
tomy group and an SLN biopsy alone group. SLN status is shown ining a mixture of eight histopathologically positive and eight negative LNs. The LNs were
topathologically positive and negative LNs. The selected mRNA markers [KRT19, KRT15,
16 histopathologically positive (● and ▲) and 16 negative (○ and△) LNs. The LNs were
B, serpin peptidase inhibitor, clade B member; PI, peptidase inhibitor; ANXA8, annexin
CC, squamous cell carcinoma; AC, adenocarcinoma.
Fig. 3. (A) KRT19 mRNA expression in the OSNA assay carried out under the protocol shown in Fig. 1A. (Column A) Histopathologically negative LNs removed from pN0 patients.
(Column B) Histopathologically negative LNs removed from pN1 patients. (Column C) Histopathologically positive LNs. Dotted lines correspond to a cutoff value of 250 copies/μL.
Two of the 22 histopathologically positive LNs (from 2 patients) showed fewer than 250 copies/μL (37 and 100 copies/μL) of KRT19 mRNA. These 2 LNs were diagnosed by histo-
pathological examination as isolated tumor cells. (B) Receiver operating characteristic curves depicting the sensitivities and speciﬁcities of serial cutoff values (25–5000 copies/μL).
KRT, cytokeratin; OSNA, one-step nucleic acid ampliﬁcation; LN, lymph node; AC, adenocarcinoma.
534 S. Okamoto et al. / Gynecologic Oncology 130 (2013) 530–536Table 1. The median number of resected LNs in the systematic pelvic
lymphadenectomy groups was 40 (range, 24 to 57). None of the 32
patients has experienced a recurrence and all patients are alive after
a median follow-up time of 24.5 months (range 3–47 months). We
compared the results of the OSNA assay using KRT19 mRNA with
the histopathological diagnosis (Table 2). Histopathological diagnosis
revealed six positive SLNs and 124 negative SLNs, while the OSNA
assay revealed ﬁve positive SLNs and 125 negative SLNs. Concordance
rate between the two-mm interval histopathological examination
and the OSNA assay was 96.2%, with a sensitivity of 50% and a speci-
ﬁcity 98.4%. Discordant cases were analyzed as shown in Table 3.
Discussion
With serial sectioning and IHC, SLN micrometastases have been
detected in 1.7–20% of cervical cancer patients [2,11,23–30]. However,
serial sectioning combined with IHC is difﬁcult, time-consuming, and
expensive, even if limited to SLNs. On the other hand, recently reported
qRT-PCR methods show promise as diagnostic tools because they are
highly sensitive, require relatively less time to perform, and are cost ef-
fective [15,31]. The OSNA assay is currently in clinical use for the diag-
nosis of LN metastases in breast cancer and is being investigated for
potential use for LN metastases in gastric and colorectal cancers, with
KRT19 mRNA as the molecular marker [19–21,32–36]. Compared to
qRT-PCR, the OSNA assay is easy to perform and rapid enough to be
done during surgery. Another advantage of the OSNA method was
that the KRT19 primers used were designed with no ampliﬁcation of
KRT19 pseudogenes [17].
In this study, KRT19 mRNA was considered one of the optimal
markers for OSNA. When the cutoff value was 250 copies/μL, the
concordance rate was high between the OSNA assay and two-mmTable 2
Concordance between the OSNA assay and 2-mm-interval histopathological examination.
SLN Histopathological examination
n = 130 Mac Mic ITC Neg
OSNA assay
Positive 2 1 0 2
Negative 0 3 0 122
Concordance rate: 96.2%, sensitivity: 50.0%, speciﬁcity: 98.4%.
OSNA, one-step nucleic acid ampliﬁcation; SLN, sentinel lymphnode;mac,macrometastasis;
mic, micrometastasis; ITC, isolated tumor cell; neg, negative.interval histopathological examination. Van Trappen et al. examined
KRT19 mRNA expression by RT-PCR and they showed that KRT19
mRNA had high speciﬁcity as a molecular marker in LNs from patients
with cervical cancer [37]. They analyzed 32 LNs from patients with
benign epithelial disease. Only one showed expression of KRT19 tran-
scripts, and its expression was at a very low level. On the other hand,
Häfner et al. and Yuan et al. reported that HPV 16 E6 and SCCAmRNAs,
respectively, were more suitable for the detection of tumor cells in
SLNs from cervical cancer patients than KRT19 mRNA [22,38]. They
concluded that the KRT19 mRNA marker was expressed in normal
LNs and was therefore not suitable for molecular detection of micro-
metastatic cervical cancer. In the study by Häfner et al., the median
KRT19 copy number differed by 10,000-fold or more between positive
LNs and normal control LNs. Positive LNs and normal control LNs may
have exhibited a signiﬁcant difference due to the increased number of
samples. In the study by Yuan et al., the median KRT19 copy number
differed by 40,000-fold or more between positive LNs and normal
control LNs. According to the Häfner et al. and Yuan et al. studies,
KRT19 mRNA seemed to be a suitable marker, if the proper cutoff
value could be set. Thus, our results showed no contradiction to the
previous reports and these ﬁndings also proved the efﬁcacy of the de-
tection of KRT19mRNA by OSNA assay. In our study, the expression of
HPV 16 E6 mRNA was low in AC metastatic LNs, and SERPINB3 (SCCA
mRNA) did not differ between histopathologically positive and nega-
tive LNs. Based on the results of Häfner et al., we think that the detec-
tion of E6 mRNA in HPV 16-positive cases may give proper results.
However, HPV 16 was detected in approximately 54% of all patients
with SCCs while ACs were found in 32% or 42% of patients [39,40].
Thus, when HPV 16 E6 mRNA marker was used in LN diagnosis, in
SCCs and ACs, false negative will occur approximately 50% of the
time. Therefore, HPV 16 E6 and SCCA mRNAs were not identiﬁed asTable 3
Discordant case analysis.
Sample 2-mm-interval histology OSNA qRT-PCR using CK19
Odd NB Even NB Copies/μL (Ct values)
1 Micro (0.6 mm) – ND 33.6
2 Micro (1.0 mm) – ND 36.8
3 Micro (1.05 mm) ITC (0.15 mm) ND 32.7
4 – – 280 28.0
5 – – 280 29.5
OSNA, one-step nucleic acid ampliﬁcation; NB, number block; micro, micrometastasis;
ITC, isolated tumor cell; ND, not detected.
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believe that it would be simpler and more practical if LN metastasis
could be diagnosed by a single marker. Thus, based on our results,
KRT19 mRNA can be used as a suitable marker since it is not affected
by histologic type or HPV type.
In performance evaluation, a total of ﬁve discordant SLNs were ob-
served (Table 3). Three histopathologically positive SLNs showed less
than 250 copies/μL in the OSNA assay. In two of three SLNs, no metas-
tases were observed in even numbered block surfaces by histopatho-
logical examination. Further examination of the OSNA assay samples
by qRT-PCR assessment of KRT19 mRNA showed that the Ct values
were the same as histopathologically negative LNs. We believe that
the portion of the LN that contained the micrometastatic lesion was
sent for histopathological examination whereas the portion sent for
OSNA assay lacked the lesion. In another SLN, block two, which was
used for OSNA analysis, had only an ITC by histopathological exami-
nation. Further examination showed that the Ct value was the same
as histopathologically negative LNs according to qRT-PCR assessment
of KRT19 mRNA. Since the OSNA assay is not designed to recognize
tumor cells corresponding to ITCs, the OSNA assay revealed a
negative LN status. Additionally, two histopathologically negative
SLNs showed greater than 250 copies/μL in the OSNA assay. In both
SLNs, the remaining pathologic specimen was sectioned at 0.1 mm
intervals and examined with H&E and IHC for CK (AE1/AE3). Metasta-
ses were not detected in these blocks. Further examination was
performed and the results showed that the Ct values were less than
those of histopathologically negative LNs when assessed by qRT-PCR
for KRT19 mRNA. We believe that the portion of the LN containing
the micrometastatic lesion was sent for OSNA assay whereas the por-
tion analyzed by histopathological examination was free of detectable
disease. In this study, we detected three micrometastatic LNs by his-
topathology. The copy numbers of three micrometastases with SCC
were 400, 920 and 1100 copies/μL. Since the copy numbers of two
SLNs that were negative by histopathology were close (400 copies/μL)
to the three micrometastases, we speculate that two of the negative
SLN cases hadmicrometastases. It is likely that themain cause of discor-
dance was tissue allocation bias. In other words, if the OSNA assay had
been performed on whole LNs, it might have detected foci from both
micrometastases and macrometastases. If the results of the OSNA
assay were positive, we believe that adjuvant therapy would be neces-
sary or since false positive by OSNA assay is very less, we consider that
LN has metastasis.
In conclusion, when KRT19 mRNA is assessed by OSNA, LN metas-
tases can be detected as accurately as by conventional histopatholog-
ical techniques. KRT19 mRNA was shown to be useful for the OSNA
assay in cervical cancer patients. In additional studies, extending val-
idation to SLNs will be necessary.Disclosure statement
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